These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18073150)

  • 1. In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp.
    Barchiesi F; Giacometti A; Cirioni O; Arzeni D; Kamysz W; Silvestri C; Licci A; Marigliano A; Della Vittoria A; Nadolski P; Łukasiak J; Scalise G
    J Chemother; 2007 Oct; 19(5):514-8. PubMed ID: 18073150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans.
    Barchiesi F; Giacometti A; Cirioni O; Arzeni D; Silvestri C; Kamysz W; Abbruzzetti A; Riva A; Kamysz E; Scalise G
    Peptides; 2007 Aug; 28(8):1509-13. PubMed ID: 17698253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes.
    Simonetti O; Silvestri C; Arzeni D; Cirioni O; Kamysz W; Conte I; Staffolani S; Orsetti E; Morciano A; Castelli P; Scalise A; Kamysz E; Offidani AM; Giacometti A; Barchiesi F
    Mycoses; 2014 Apr; 57(4):233-9. PubMed ID: 26058322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinical isolates of Candida spp.
    Kamysz E; Simonetti O; Cirioni O; Arzeni D; Ganzetti G; Campanati A; Giacometti A; Gabrielli E; Silvestri C; Kamysz W; Offidani A; Barchiesi F
    Peptides; 2011 Jan; 32(1):99-103. PubMed ID: 21055432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
    Oz Y; Akşit F; Kiraz N; Kiremitçi A
    Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi.
    Nakajima R; Kitamura A; Someya K; Tanaka M; Sato K
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1517-21. PubMed ID: 7492096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fungicidal efficacy of various honeys against fluconazole-resistant Candida species isolated from HIV
    Shokri H; Sharifzadeh A
    J Mycol Med; 2017 Jun; 27(2):159-165. PubMed ID: 28159362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by farnesol.
    Cordeiro RA; Teixeira CE; Brilhante RS; Castelo-Branco DS; Paiva MA; Giffoni Leite JJ; Lima DT; Monteiro AJ; Sidrim JJ; Rocha MF
    Med Mycol; 2013 Jan; 51(1):53-9. PubMed ID: 22712455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
    De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
    J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species].
    Altuncu E; Bilgen H; Cerikçioğlu N; Ilki A; Ulger N; Bakır M; Akman I; Ozek E
    Mikrobiyol Bul; 2010 Oct; 44(4):593-603. PubMed ID: 21063972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro synergistic effect of moxifloxacin and amphotericin B combination against Candida strains].
    Yalçin B; Kalkanci A; Gürelik F; Fidan I; Kustimur S; Ozdek S
    Mikrobiyol Bul; 2010 Jan; 44(1):65-70. PubMed ID: 20455400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fungicidal Potency and Mechanisms of θ-Defensins against Multidrug-Resistant Candida Species.
    Basso V; Garcia A; Tran DQ; Schaal JB; Tran P; Ngole D; Aqeel Y; Tongaonkar P; Ouellette AJ; Selsted ME
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment.
    Woodburn KW; Clemens LE; Jaynes J; Joubert LM; Botha A; Nazik H; Stevens DA
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
    J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp.
    Wardle HM; Law D; Denning DW
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2229-31. PubMed ID: 8878616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal activity of miconazole against recent Candida strains.
    Isham N; Ghannoum MA
    Mycoses; 2010 Sep; 53(5):434-7. PubMed ID: 19531099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates.
    Alves SH; Da Matta DA; Azevedo AC; Loreto ES; Boff E; Santurio JM; Guarro J
    Mycoses; 2006 May; 49(3):220-5. PubMed ID: 16681814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.
    Pinto PM; Weikert-Oliveira Rde C; Lyon JP; Cury VF; Arantes RR; Koga-Ito CY; Resende MA
    Microbiol Res; 2008; 163(5):579-85. PubMed ID: 16962755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.